Latest Commercialisation News

Sparc Hydrogen has reached a pivotal milestone with sustained hydrogen generation at its Roseworthy pilot plant, advancing its innovative photocatalytic water splitting technology towards commercialisation.

Terragen Holdings has received nearly $1 million in R&D tax incentives, reinforcing its cash position and fueling ongoing development of its innovative agricultural biotech products.

Identitii Limited has announced a pro rata non-renounceable rights issue to raise approximately $2.88 million, partially underwritten by Beauvais Capital Pty Ltd. The funds will support the development and commercialisation of its BNDRY platform amid ongoing patent litigation risks.

Anteris Technologies has secured regulatory green lights for its pivotal PARADIGM trial and raised $25.2 million in capital, advancing its innovative DurAVR® transcatheter heart valve towards commercialisation.

HITIQ Limited has successfully raised $925,000 through an oversubscribed placement, issuing shares at a discount and attaching listed options to support its concussion management technology's commercialisation.

Neurizon Therapeutics has completed manufacturing three GMP registration batches of its lead ALS drug candidate NUZ-001 ahead of schedule, paving the way for FDA submissions and clinical trial enrollment.

4DMedical has expanded its partnership with Philips, securing a US$10 million order commitment to distribute its CT – VQ™ lung imaging technology across North America, aiming to transform pulmonary diagnostics.

Talga Group has applied for a SEK 1.1 billion grant to fund a commercial-scale battery anode plant in Sweden, complementing existing EU funding and securing strong customer interest.

Nexsen Limited has appointed internationally acclaimed surgeon-scientist Professor Shekhar Kumta to its board, aiming to fast-track clinical validation and regulatory approval for its rapid diagnostic platforms ahead of a planned 2026 market entry.

Invion Limited has expanded its global rights to the Photosoft™ technology, gaining exclusive perpetual licenses across a broad range of human and animal diseases, including cancers and infectious diseases. This milestone-based deal positions Invion to accelerate clinical development and commercialisation worldwide.

Optiscan Imaging Ltd has initiated Australia’s first intra-operative head and neck cancer imaging study using its advanced InVue® and InForm™ devices, aiming to enhance surgical precision and support FDA regulatory submissions.

ABx Group has produced its maiden mixed rare earth carbonate from Tasmania’s Deep Leads deposit, boasting dysprosium and terbium contents far exceeding peers and commanding a premium basket price.